Phase 4Status unknown
A real world study to evaluate safety and effectiveness of Topical Esmolol in chroic Diabetic Foot Ulcer Healing
A multicentric real world prospective study to evaluate safety and effectiveness of Topical Esmolol 14 percentage as a pro Angiogenic agent in chroic Diabetic Foot Ulcer Healing - NIL
- Sponsor
- IPCA Laboratories
- Enrolment
- 750 planned
- Conditions
- Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
- Interventions
- Esmolol 14 percent Topical cream
- Registry
- CTRI-2026-08-115457
Full record on the Clinical Trials Registry – IndiaSource: WHO ICTRP, processed 14 September 2026
Primary outcomes
- To assess the clinical effectiveness of topical esmolol in achieving complete re epithelialization ulcer closure when administered adjunctively with standard wound care of target diabetic foot ulcers digitally captured through APIC appTimepoint: At Week 4 8 and 12
History
Last registry update
Started
Registered